Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
2021 Year in Review - Multiple Myeloma
2021 Year in Review: Advances in Dual IO Cancer Treatments
2021 Year in Review - Breast Cancer
2021 Oncology Drug Coding and Updates
2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer
2021 Year in Review - Biosimilars
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2021 Novel Oncology Drug Approvals
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
ASH 2021 - AML
ASH 2021 - Myelofibrosis
2021 Myelofibrosis Wrap-Up
AACR & ASCO 2021 - Midyear Review
ASCO 2021 - Lung Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2019
November 2019, Vol 9, No 11
November 2019, Vol 9, No 11
Delivering High-Value Personalized Interventions
By
Chase Doyle
Value-Based Care
As the treatment landscape in oncology changes on a seemingly daily basis, providers face increasingly complex decisions, and it is not just the myriad of therapies available: oncologists must balance drug efficacy and toxicity, clinical outcomes, and patient quality of life, all while providing value-based care. Enter clinical pathways, a multidisciplinary management tool used to guide evidence-based care for subgroups of patients with predictable clinical courses.
Read Article ›
Patient-Centered Clinical Pathways Should Incorporate the Patient’s Voice
By
Chase Doyle
Personalized Medicine
Patient-centered clinical pathways may hold the promise of truly personalized medicine, improving value-based care and clinical outcomes. However, according to Cary P. Gross, MD, Director, Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale School of Medicine, New Haven, CT, substantial challenges still stand in the way of including the patient’s voice in these pathways.
Read Article ›
Oral Parity Laws Could Reduce Disparities in Cancer Care
By
Chase Doyle
Health Policy
Great progress has been made in the fight against cancer, but not all patients have benefited equally. Disparities exist among specific populations in terms of survival and cancer-related mortality, incidence and prevalence, as well as adverse health conditions, according to Karen M. Winkfield, MD, PhD, Director, Office of Cancer Health Equity, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, NC. Dr Winkfield discussed the topic at the 2019 ASCO Quality Care Symposium.
Read Article ›
Financial Toxicity High for Low-Income Patients in Early-Phase Clinical Trials
By
Chase Doyle
Financial Toxicity
The economic burden faced by patients with cancer who have low income may be more pervasive than previously thought. According to data presented at the 2019 ASCO Quality Care Symposium, even patients enrolled in clinical trials are at high risk for financial toxicity.
Read Article ›
Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management
By
Chase Doyle
Cholangiocarcinoma
Diagnosis of cholangiocarcinoma (CCA) is often identified at a late stage. Analyzing the tumor-specific mutation profile of a patient with CCA can improve the diagnosis and treatment for the individual patient. The molecular profile of CCA can be done through the use of circulating tumor (ct) DNA sequencing, which may help to target specific mutations and improve treatment selection for this rare type of cancer.
Read Article ›
Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials
By
Chase Doyle
Clinical Trials
New research sponsored by the National Cancer Institute highlights the uphill battle faced by patients with limited financial resources even in clinical trials. According to data presented at the 2019 ASCO Quality Care Symposium, patients with Medicaid or with no insurance had significantly worse overall survival in positive clinical trials compared with privately insured patients.
Read Article ›
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
By
Phoebe Starr
ESMO Highlights
Late-breaking data from 2 clinical trials presented at ESMO 2019 will likely change the treatment paradigm for pre- or postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer, regardless of menopausal status. The MONALEESA-3 study and the MONARCH-2 study showed an improved overall survival (OS) with the addition of the CDK4/6 inhibitor ribociclib (Kisqali) or abemaciclib (Verzenio) to endocrine therapy as first- or second-line therapy. The results were presented at the Presidential Session of the meeting.
Read Article ›
The Flaw in Infusion Scheduling
By
Ina Huang
Practice Management
With the goal of treating as many patients as possible with the highest level of care and respect, infusion centers often mistakenly operate under the logic that appointments must be scheduled well before they occur—that by booking early and locking things down, schedules will run smoothly and accommodate more patients. In reality, scheduling appointments with significant lead times, often weeks or months before the actual appointment, may actually cause more problems and serve fewer patients. Therefore, it is worth reconsidering how infusion centers schedule appointments.
Read Article ›
FDA Approves Erleada for Metastatic Castration-Sensitive Prostate Cancer
FDA Approvals, News & Updates
On September 17, 2019, the FDA approved a new indication for apalutamide (Erleada; Janssen Biotech) for the treatment of patients with metastatic castration-sensitive prostate cancer (CSPC). Apalutamide was initially approved in 2018 for the treatment of nonmetastatic castration-resistant prostate cancer. The FDA granted apalutamide priority review for the new indication.
Read Article ›
Keytruda plus Lenvima Regimen FDA Approved for Advanced Endometrial Carcinoma with No MSI-H or dMMR Tumors
FDA Approvals, News & Updates
On September 17, 2019, the FDA accelerated the approval of a new combination of pembrolizumab (Keytruda; Merck) plus lenvatinib (Lenvima; Eisai) for patients with advanced endometrial carcinoma that is not associated with microsatellite instability high (MSI-H) or mismatch repair–deficient (dMMR) tumors in patients whose disease progressed after systemic therapy and who are candidates for curative surgery or radiation. The FDA granted this application priority review and a breakthrough therapy designation.
Read Article ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
2022 Midyear Review: Non–Small-Cell Lung Cancer
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Oncology Guide to Patient Support Services Index
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
2021 Year in Review - Multiple Myeloma
2021 Year in Review: Advances in Dual IO Cancer Treatments
2021 Year in Review - Breast Cancer
2021 Oncology Drug Coding and Updates
2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer
2021 Year in Review - Biosimilars
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2021 Novel Oncology Drug Approvals
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
ASH 2021 - AML
ASH 2021 - Myelofibrosis
2021 Myelofibrosis Wrap-Up
AACR & ASCO 2021 - Midyear Review
ASCO 2021 - Lung Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
OPM
Print Edition
OPM
Weekly e‑Newsletter
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
OPM
's
Privacy Policy
, and
OPM
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION